Navigation Links
Senomyx Announces Management Update
Date:9/24/2013

e are making excellent progress implementing our new direct sales strategy, under which Senomyx will sell certain of our ingredients directly to flavor companies.  This strategy complements the Company's existing licensing collaborations and provides a new avenue for commercial growth to accelerate the time to profitability," Poyhonen noted.

"This is an exciting time for Senomyx as we continue to make significant progress with our research and development activities in addition to our commercialization efforts," Poyhonen said.  "We are identifying and optimizing new discoveries that could expand our market opportunities for our partners under our collaborative agreements and add new flavor ingredients to our direct sales product portfolio." 

About Senomyx, Inc. (www.senomyx.com)

Senomyx is using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients.  These include modifiers of Sweet and Salt flavors as well as Savory Flavors, Bitter Blockers, and Cooling Agents.  The Company is also engaged in an effort to discover and develop natural high-potency sweeteners.  Under its direct sales initiative, Senomyx is beginning to sell certain of its flavor ingredients to flavor companies for re-sale to their food and beverage company customers.  In addition, Senomyx has collaborative agreements with global food, beverage, and ingredient supply companies, some of which are currently marketing products that contain Senomyx's flavor ingredients.  Senomyx's corporate socially responsible activities are described on the Senomyx Cares blog at '/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
3. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
5. SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS
6. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE
7. SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER FINANCIAL RESULTS
8. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE MIDWEST IDEAS INVESTOR CONFERENCE
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
10. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... 04, 2015 , ... November Research Group, LLC, a global ... to pharmaceutical and life sciences organizations, today announced the production implementation of its ... data intake solution that enables field sales representatives, clinical research associates, and product ...
(Date:9/3/2015)... 3, 2015 /PRNewswire/ - bioLytical Laboratories Inc., a leader ... study " Sensitivity of a rapid point of care ... its affinity for HIV gp41 IgM antibodies " has ... study highlights INSTI,s ability to detect early HIV infection.  ... the 8 th annual International AIDS Society Conference, ...
(Date:9/3/2015)... ... ... If you plan to attend the 27th annual Tradeline College and University ... up for the tour of Framingham State University's newest addition to Hemenway Hall taking ... (8) chemistry teaching labs that are exclusively utilizing (49) filtered fume hoods that ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Biochips ... to their offering. This report is ... and applications. The report starts with a description ... markets. Technologies include array comparative genomic hybridization (CGH), ...
Breaking Biology Technology:November Research Group’s PRIMO Mobile Goes Live at Allergan Japan 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2
... 28, 2012 Regado Biosciences, Inc., a privately held company ... announced that David J. Mazzo, PhD, President and CEO, will ... Annual Health Care Conference at 1:30 p.m. EST on March ... MA.  The presentation will include an overview ...
... ViroPharma Incorporated (Nasdaq: VPHM ) reported today its ... 31, 2011. In 2011, we: Achieved ... $251 million in net sales of Cinryze® (C1 esterase inhibitor ... Hydrochloride Capsules, USP); Attained non-GAAP adjusted net income of ...
... 28, 2012 Ultragenyx Pharmaceutical Inc., a biotechnology ... ultra-rare genetic disorders, today announced that the FDA ... drug designation for UX003 for the treatment of ... autosomal recessive lysosomal storage disorder characterized by a ...
Cached Biology Technology:Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA 2Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 12Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 3
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... A new study has found that the allergenicity of ... fermentation process. Researchers from North Carolina A&T University report ... the American Society for Microbiology. , "Due to the ... cookies, snacks and even soups there is a need ...
... viral-based therapies for cancer , Researchers at Columbia University ... to develop the next generation of effective viral-based therapies ... genetically engineered viruses studied in mice, published today in ... National Academy of Sciences (PNAS), bring us significantly closer ...
... have had an accelerated childhood compared to that of modern ... by researchers from Ohio State University and the University of ... tooth growth present in the Neanderthal fossils they examined was ... , And since the rate of tooth growth has ...
Cached Biology News:Columbia scientists develop cancer terminator viruses 2Columbia scientists develop cancer terminator viruses 3Neanderthal teeth grew no faster than comparable modern humans' 2Neanderthal teeth grew no faster than comparable modern humans' 3
... The DNA Engine Tetrad thermal cycler ... the pioneering PTC-200 DNA Engine cycler. ... the capacity with a footprint only ... throughput for laboratories that run massive ...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... PROTEAN II xi multi-cell is for 2-D separations. ... cooling capabilities. The PROTEAN II xi multi-cell can ... type of glass plates, and cooling system. The ... to the PROTEAN II XL multi-cell for a ...
Biology Products: